Mike F.

[Ocugen @Ocugen]

Thank you to everyone who joined this year’s Clinical Trials at the Summit. Ocugen Chairman, CEO, and Co-Founder @drsmusunuri joined industry leaders for a panel discussion on IRDs and the importance of advancing innovative gene therapies. $OCGN #GeneTherapy #Biotech

[Ocugen @Ocugen]

Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ +6 letter gain in visual acuity

Hear from an OCU410ST clinical trial participant: https://t.co/znh5I8UL9R

$OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

@Ocugen @drsmusunuri 👏👏👏

https://t.co/Ip2AIVGfzF

[Ocugen @Ocugen]

What is #RetinitisPigmentosa (RP)?

RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN

https://t.co/MezalmKsVp

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
Read between the lines.... @NeenaHaider 👏👏👏🙏🙏🙏 @Ocugen

[Ocugen @Ocugen]

100,000+ people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, with early promising data.

Follow Ocugen and be part of something groundbreaking. #Biotech #Genetherapy $OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
#Russell3000 and #Russell2000

Hope you guys are aware of that!!!

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
#Oppenheimer 💥
Nothing in this business just happens!!!
I believe it is all planned out!!!

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

FTSE Russell released the preliminary 2026 additions list on May 22, 2026 and @Ocugen is included 👇

The reconstitution takes effect after market close on June 26, 2026, so $OCGN will officially join at the open on Monday, June 29, 2026

A positive development for visibility and potential passive inflows, some will only buy Russell's 3000.

[Ocugen @Ocugen]

Impactful day in Ft. Lauderdale at #RetinaWorldCongress as CEO @drsmusunuri shared how Ocugen is advancing potentially one-time gene therapies for RP, Stargardt disease, and GA, while working toward three BLA filings by 2028.

@RWCRetina #GeneTherapy #Biotech $OCGN

[Ocugen @Ocugen]

Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.

Learn more: https://t.co/7nSj5EJkPZ

#GeneTherapy #Biotech #FinancialUpdate $OCGN

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN #OCU400EAP
@Ocugen..... I wander if it is time for any info?

Study Details | NCT06574997 | Expanded Access Program for RP in Adults | https://t.co/6jWgMIZvPU https://t.co/1IkeqeAHMP

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

Ocugen (OCGN) upgraded to buy: Here's why https://t.co/TMpWsMuZfa

[Billythekid123 @B1llyTh2K3d]

Doing my part to spread this around further as the author did an incredible job of compiling key data and facts about OCU500 $OCGN

Facts the #OcuFam already knows but a beautifully succinct article of information for newcomers.

https://t.co/WUVPHpOapk

[Ocugen @Ocugen]

During #ARVO2026, Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements through automation for #geographicatrophy & #Stargardtdisease. Proud to support innovation advancing research for blindness diseases. $OCGN #AMD @ARVOinfo

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

Oppenheimer 💥💥💥
That is huge !!!

https://t.co/C8VYI2ZSew

[Billythekid123 @B1llyTh2K3d]

One last post to really hammer my point home.

Ocugen just secured a $130M loan at a conversion price of $2.68/share while the stock was trading below $2.00.

They won’t have to pay anything back til 2032.

We’ll make a billion in 2027 alone.

Good night. Fear not. 🤙 $OCGN

[Ocugen @Ocugen]

Today, CEO @drsmusunuri announced 1Q 2026 update:
• Cash runway into 2028
• Positive #OCU410 data
• Enrollment complete for #OCU400 & #OCU410ST
• Progress toward BLA filings
Read: https://t.co/XrxOFhqbP8
#EarningsUpdate #Genetherapy $OCGN